about
Characteristics and outcomes of Canadian MD/PhD program graduates: a cross-sectional survey.Epigenomic alterations define lethal CIMP-positive ependymomas of infancyScientific overview: CSCI-CITAC Annual General Meeting and Young Investigator's Forum 2013.Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype.Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma.TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma.Fostering mentorship for clinician-investigator trainees: overview and recommendations.The Rising Challenge of Training Physician-Scientists: Recommendations From a Canadian National Consensus Conference.Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.Here to stay: clinician investigator training in a changing environment."miR miR on the wall, who's the most malignant medulloblastoma miR of them all?"Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells.PTPS-08HEMATOGENOUS DISSEMINATION OF MEDULLOBLASTOMA METASTASES TO THE LEPTOMENINGES.MB-08FUNCTIONAL ROLES OF CCL2 IN MEDULLOBLASTOMA LEPTOMENINGEAL METASTASIS.MB-16NOTCH1 PROMOTES GROUP 3 MEDULLOBLASTOMA METASTASIS, INITIATION AND SELF-RENEWAL.ATOH1 Promotes Leptomeningeal Dissemination and Metastasis of Sonic Hedgehog Subgroup Medulloblastomas.Scientific overview: CSCI-CITAC Annual General Meeting and Young Investigators' Forum 2014.Scientific overview: CSCI - CITAC Annual General Meeting and Young Investigator's Forum 2012.It begins with the right supervisor: importance of mentorship and clinician-investigator trainee satisfaction levels in Canada.FORETINIB IS EFFECTIVE THERAPY FOR METASTATIC SONIC HEDGEHOG MEDULLOBLASTOMA.
P50
Q33874592-EF07081E-28B8-4EBA-8FE0-8C6226D77D0EQ34240198-E0E6D3CD-8C1A-468B-AA69-D757E83076BAQ35218756-2A575A1F-5D92-43F6-B522-A9932C162DFCQ35958168-E4F29092-E977-4BC9-B63A-512608C9FF15Q36631618-B000A54E-5F9E-4CF5-BD29-5094A508399AQ37316068-2C039F10-F8DA-40CC-B812-207CF54265D2Q38120467-AC96749E-80D1-4B13-B878-44323236F1E2Q38348188-7A2EBC5A-4568-47B5-879E-EC700AEBBB89Q38640971-D888ABB7-4496-4BC1-A694-2CBA7A1BDDC1Q38940977-C23AEA3C-3107-49F9-A614-81A0B981E10EQ39340576-A94C5166-3120-4608-8254-54B3E0634F82Q39346476-2F76D30E-B6BB-4BB2-9880-297B8765D8C9Q39521830-E4110197-42FF-4C09-9600-E31858136778Q45834929-130FB7E3-F933-48BF-83A2-39775A3DEFF5Q45984622-4EA455FE-C816-4B16-80E6-EF1BA44CA40CQ46354257-0F092E44-81B5-4F93-BFEE-5894BE0B75EFQ47851564-1C48983D-8353-4CEA-9195-61C80E80008DQ48028072-EB13CF3D-7788-4B89-BE4F-B04F8FBB9168Q48279284-51C93D07-8569-48F7-AF1E-43BA7AD26B6FQ48554788-29F67297-1337-4B34-BCB5-334960DF1759Q55624498-71EB21C7-CCD3-4962-B7D5-35B18709C006
P50
description
researcher ORCID: 0000-0001-8783-4080
@en
name
Xin Wang
@ast
Xin Wang
@en
Xin Wang
@es
Xin Wang
@nl
Xin Wang
@sl
type
label
Xin Wang
@ast
Xin Wang
@en
Xin Wang
@es
Xin Wang
@nl
Xin Wang
@sl
prefLabel
Xin Wang
@ast
Xin Wang
@en
Xin Wang
@es
Xin Wang
@nl
Xin Wang
@sl
P106
P31
P496
0000-0001-8783-4080